“Advanced management of intermediate-high risk pulmonary embolism (PE)” shows that there is a higher mortality rate and recurrence of PE in patients treated by repeat-dose thrombolysis compared to surgical embolectomy [1]. The study also indicates that all bleeding events in repeated thrombolytic therapy were fatal [1]. In addition, among the 174,322 patients hospitalized for PE in the New York State Registry, there was no short-term difference in mortality between these two treatments [1]. Moreover, patients who underwent surgical pulmonary embolectomy had lower rates of stroke, recurrent PE, and need for re-intervention [1]. Due to the fatal outcomes, patients who have developed chronic thromboembolic pulmonary hypertension (CTEPH) after an initial PE should not receive a second thrombolytic therapy [2]. Taking the high recurrence rates in patients with CTEPH into consideration, CTEPH should be diagnosed beforehand, and could be treated by pulmonary endarterectomy (PEA), a challenging procedure with complex patient selection and perioperative management requiring significant expertise [2, 3]. Nevertheless, if treated in time, patients can be cured, even though they may need temporarily veno-arterial or veno-venous extracorporeal membrane oxygenation (VA or VV-ECMO) [2]. Patients suffering from a PE recurrence after embolectomy should not undergo a new embolectomy treatment because of the high fatality rate, and instead should be screened quickly for CTEPH and undergo a PEA as treatment and PE prevention [2]. The management of distal thromboembolic lesions with PEA remains a challenge. Limited distal CTEPH is not considered an absolute contraindication for a PEA, with up to 50% of patients having incomplete thrombi removal or extensive pulmonary microvascular disease. Medical therapies that target the underlying pulmonary microvascular disease can offer symptomatic and hemodynamic benefits, although they do not deal with the core mechanism of the disease which require the removal of thromboembolic material from pulmonary vasculature. Recent research has provided evidence suggesting balloon pulmonary angioplasty (BPA) is one treatment option for inoperable CTEPH and recurrent/persistent pulmonary hypertension after PEA [4]. Thrombolysis and surgical embolectomy may not be the cure for everyone, especially in case of repeated PEs [3, 4]. A clear step-by-step approach needs to be implemented in case of failed thrombolysis. In the case of CTEPH, diagnosis should not be overlooked, as PEA and BPA might be lifesaving [2].
Availability of data and materials
Not applicable.
Abbreviations
- PE:
-
Pulmonary embolism
- CTEPH:
-
Chronic thromboembolic pulmonary hypertension
- PEA:
-
Pulmonary endarterectomy
- BPA:
-
Balloon pulmonary angioplasty
- VA-ECMO:
-
Veno-arterial extracorporeal membrane oxygenation
- VV-ECMO:
-
Veno-venous extracorporeal membrane oxygenation
References
Weinstein T, Deshwal H, Brosnahan SB. Advanced management of intermediate-high risk pulmonary embolism. Crit Care. 2021;25(1):311. https://doi.org/10.1186/s13054-021-03679-2.
Segel MJ, Kogan A, Preissman S, et al. Pulmonary endarterectomy surgery for chronic thromboembolic pulmonary hypertension: a small-volume National Referral Center experience. Isr Med Assoc J. 2019;21(8):528–31.
Ruaro B, Baratella E, Caforio G, et al. Chronic thromboembolic pulmonary hypertension: an update. Diagnostics. 2022;12(2):235. https://doi.org/10.3390/diagnostics12020235.
Tzoumas A, Peppas S, Sagris M, et al. Advances in treatment of chronic thromboembolic pulmonary hypertension. Thromb Res. 2022;212:30–7. https://doi.org/10.1016/j.thromres.2022.02.003 (Epub 2022 Feb 12).
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Contributions
PMH, RA designed the paper. PMH, SR, PD, SB, IB, TP, BVC, KK, LBG, SA, AG, RA participated in drafting and reviewing. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Honore, P.M., Redant, S., Djimafo, P. et al. Endarterectomy treatment for patients suffering from a new episode of pulmonary embolism, after screening for chronic thromboembolic pulmonary hypertension. Crit Care 26, 165 (2022). https://doi.org/10.1186/s13054-022-04037-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13054-022-04037-6